Overview of Glimed (Gliclazide)

Quick Facts

Property	Description
Active Ingredient	Gliclazide
Form	Tablets, Modified-release tablets (MR)
Pharmacological Class	Antidiabetic Agent (Oral Hypoglycemic Agent)
General Purpose	Management of high blood glucose (sugar)
Origin	Synthetic (Chemically derived)

What is the Medicine Glimed (Gliclazide) and Its Classification?

Gliclazide, the sole active ingredient in the prescription-only medicine Glimed, is classified as an Antidiabetic Agent, specifically an Oral Hypoglycemic Agent because it is taken by mouth to lower blood sugar levels. This compound is a chemically synthetic sulfonylurea derivative used for managing elevated blood glucose levels. Gliclazide is a second-generation sulfonylurea, a subclass recognized for its potency in stimulating insulin secretion from the pancreatic beta-cells compared to older agents.

Gliclazide is internationally recognized and is included on the WHO Model List of Essential Medicines for the pharmacological treatment of Type 2 Diabetes Mellitus. Gliclazide (as an International Nonproprietary Name) is the common active substance shared by several brands, and this pharmacological profile is recognized for its efficacy in maintaining stable glucose control in non-insulin-dependent adults.

Composition, Origin, and Available Drug Forms

As a single-ingredient product, Gliclazide is combined with solid pharmaceutical excipients to create the final product intended for oral administration. The medication is available in two primary dosage forms: standard immediate-release tablets and modified-release tablets (MR). The modified-release tablets are specifically formulated to control the rate at which the Gliclazide is absorbed into the bloodstream over time.

This specific controlled-release technology, which is a key differentiating feature of the MR form, allows for sustained therapeutic levels throughout the day. The modified-release formulation is designed to maintain stable fasting glucose levels in patients with Type 2 Diabetes. This allows the modified-release form to provide consistent, all-day blood sugar stabilization.

Gliclazide's General Purpose in Diabetes Management

The general purpose of using Gliclazide is to achieve necessary blood glucose reduction in adults with Type 2 Diabetes Mellitus. It accomplishes this by promoting insulin release, thereby improving the body's ability to regulate and utilize circulating sugar. A typical scenario for its use involves stabilizing the daily glucose levels of an adult with recently diagnosed Type 2 Diabetes. By stabilizing glucose metrics, Glimed serves as a foundational component in the long-term metabolic control required for managing the complexities of diabetes.

Regulatory References

Public Assessment Report for Gliclazide Modified Release (MR)

What side effects are possible with Glimed (Gliclazide)?

Possible Side Effects and Safety Information

Glimed (Gliclazide) is a sulfonylurea medication whose most significant and common risk is hypoglycemia (low blood sugar), which can be severe and prolonged. The risk of hypoglycemia is increased by irregular meal times, strenuous exercise, alcohol intake, and concomitant use with other blood glucose-lowering agents.

Serious Adverse Reactions

Although rare, Glimed has been associated with clinically significant and serious adverse reactions, which necessitate immediate medical evaluation. These include severe hepatic dysfunction, such as cholestatic jaundice and hepatitis, which may progress to life-threatening liver failure. Severe cutaneous reactions like Stevens-Johnson syndrome, Toxic Epidermal Necrolysis, and Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) have been reported. Rare but serious blood disorders, including agranulocytosis, aplastic anemia, and thrombocytopenia, may also occur.

Common Adverse Reactions

Other adverse reactions are generally milder and often involve the gastrointestinal system, such as nausea, vomiting, abdominal pain, diarrhea, and constipation. Skin reactions, including rash, pruritus, and urticaria, are also possible.

Safety Considerations and Contraindications

This medication is contraindicated in patients with known hypersensitivity to gliclazide or sulfonamides, Type 1 diabetes, diabetic ketoacidosis, and severe hepatic or renal impairment. Due to increased susceptibility to hypoglycemia, elderly patients and those with malnutrition or certain endocrine disorders require particular caution. The drug is not recommended for use during pregnancy or lactation. Patients with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency are advised to use caution due to the risk of hemolytic anemia. Regular monitoring of blood glucose, liver function, and renal function is a mandatory part of the safety profile.

Overdose and Emergency Response

Overdose Manifestations

Gliclazide overdose primarily results in severe or prolonged hypoglycaemia, the most frequent manifestation documented in regulatory sources. Initial clinical signs include a cluster of neurological and adrenergic symptoms such as headache, confusion, tremor, and lassitude, often accompanied by sweating, tachycardia, and palpitations. Gastrointestinal symptoms like nausea and vomiting may also be present.

Severe Outcomes and Emergency Action

Overdose may lead to severe outcomes documented in official labeling, including the loss of consciousness (coma), convulsions (seizures), and the potential for neurological damage or a fatal outcome. Regulatory guidance strictly mandates that immediate medical treatment or hospitalization is required when the hypoglycaemic episode is determined to be severe or prolonged.

Individuals experiencing any signs of overdose must call the local emergency number (such as 911) or a Poison Control Center immediately. Supportive management focuses on the administration of intravenous glucose (dextrose) to correct the metabolic imbalance. Prolonged observation periods are required due to the risk of hypoglycemia recurrence. Official labeling notes that infants, children, and older people are among the most vulnerable populations for serious complications.

Therapeutic Uses of Glimed (Gliclazide)

What Glimed (Gliclazide) Treats: Main Uses and Benefits

Glimed (Gliclazide) may be part of symptomatic management as an oral anti-diabetic agent in the management of Type 2 Diabetes Mellitus in adults. Its primary role helps provide consistent support for metabolic health when dietary adjustments and physical activity alone are insufficient to maintain blood sugar within a healthy range.

Gliclazide is applied in conditions presenting with systemic or localized discomfort, such as high blood glucose (hyperglycemia) associated with Type 2 Diabetes. The medication is relevant for easing symptoms related to systemic imbalance, such as unusual thirst or fatigue, and is used for managing the primary indications of Type 2 Diabetes Mellitus and chronic blood glucose elevation. The therapeutic benefit supports the patient during difficult episodes by easing distress related to systemic imbalance and may assist with managing average glucose (HbA1c).

Gliclazide is relevant in contexts where patients experience disruptive fluctuations in blood sugar, and specifically addresses symptoms related to systemic imbalance and episodic or fluctuating manifestations of sugar levels. Its sustained use is relevant when supportive symptom management is appropriate and contributes to improved comfort during periods of heightened symptoms. This support is considered relevant for metabolic stability and general well-being.

Quick Fact: Relief for Hyperglycemia
Primary Use: Management of Type 2 Diabetes Mellitus when lifestyle changes fail.
Symptom Focus: Helps manage symptoms related to systemic imbalance and persistent high blood sugar.
Patient Benefit: Supports daily glycemic stabilization and long-term HbA1c management.

Regulatory References

Therapeutic Goods Administration (TGA) Product Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Glimed (Gliclazide)?

This section outlines the population eligibility rules for Gliclazide based strictly on government regulatory documents.

Approved and Contraindicated Populations

Gliclazide is officially indicated only for adults with Type 2 Diabetes Mellitus. Use is not recommended in the pediatric population (under 18 years of age) because safety and effectiveness have not been established. While older adults can use the medicine, they may require careful monitoring due to an increased risk of hypoglycemia.

Classification	Who Must Not Use (Contraindicated)
Diabetes Status	Patients with Type 1 diabetes or acute conditions like diabetic keto-acidosis and diabetic coma.
Physiological State	Women who are pregnant or breastfeeding (lactation).
Organ Function	Individuals with severe renal insufficiency or severe hepatic insufficiency.
Hypersensitivity	Patients with known allergy to Gliclazide, other sulfonylureas, or sulfonamides.
Comorbidity	Those receiving concomitant treatment with miconazole (systemic or oromucosal gel).

Eligibility-Related Restrictions

Caution or temporary conversion to insulin therapy may be required during stress conditions such as serious infection, trauma, or surgery. Special care is also advised for patients with G6PD-deficiency or those who are malnourished, due to the increased risk of adverse effects.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Gliclazide (Glimed) as classified by government regulatory authorities.

Interaction Classifications

Classification	Official Regulatory Constraint
Contraindicated Combination	Co-administration with Miconazole (systemic or oromucosal gel) is formally prohibited due to the severe risk of potentiating the blood glucose lowering effect, potentially leading to coma.
Combinations Not Recommended	Concurrent use of Phenylbutazone (systemic route), the herbal product St. John's Wort, and alcohol are advised against due to the risk of either dangerous hypoglycemia or loss of blood sugar control.

Pharmacodynamic and Exposure Interactions

The regulatory profile identifies two primary types of interaction outcomes:

Potentiation of Hypoglycaemia: Concomitant use with agents such as other Antidiabetic Agents, Beta-blockers, ACE Inhibitors, or Fluconazole may cause an additive effect, substantially increasing the risk of low blood sugar.
Reduction of Efficacy: Substances with intrinsic hyperglycaemic effects, including Danazol, Glucocorticoids, and high-dose Chlorpromazine, may counteract Gliclazide's action. Rifampicin also decreases Gliclazide exposure by increasing its metabolism.

Population-Specific Notes

The regulatory label includes specific cautions for elderly patients using Fluoroquinolones due to reported disturbances in blood glucose. Patients with severe hepatic or renal impairment have an increased risk of severe and prolonged hypoglycaemic episodes due to altered clearance.

Mechanism of Action

Gliclazide acts by engaging a precise molecular cascade within the pancreatic β-cells, which stimulates the release of insulin. This action is defined by two primary domains: molecular targeting and electrochemical signal modulation.

⏶ Targeted Blockade of the β-Cell K ATP Channel

The drug's action begins with high-affinity binding to the Sulfonylurea Receptor 1 ( SUR1) subunit of the ATP-sensitive potassium channel ( K ATP channel) on the β-cell surface. This molecular interaction immediately causes the channel to block the outward flow of potassium ( K^+) ions. This localized ion channel inhibition initiates the sequence of molecular events leading to cellular secretion.

Electrochemical Signal Modulation and Exocytosis

Preventing K^+ efflux causes the cell membrane to depolarize, acting as an electrochemical switch that opens neighboring voltage-dependent calcium ( Ca^2+) channels. The resulting Ca^2+ influx acts as the necessary chemical signal for insulin exocytosis, leading to a surge of insulin into the circulation. This system-level increase in insulin promotes the transfer of glucose into peripheral tissues.

Dosage and Administration Information

The administration of Glimed (Gliclazide) is defined by its formulation, with all use restricted to the oral route. Gliclazide is available as Standard (IR) Tablets and Modified-Release (MR) Tablets, each with specific rules for dosing and administration.

Official Dosing and Frequency

The initial recommended dose for the MR formulation is 30 mg once daily, with the dose titrated according to metabolic response. The maximum labeled dose for the MR form is 120 mg daily. For the IR formulation, the starting dose ranges from 40 mg to 80 mg daily, and the maximum daily dose is 320 mg. Doses of IR Gliclazide exceeding 160 mg must be administered in divided doses.

Administration Requirements

The single daily dose of Gliclazide MR must be taken with breakfast to maintain consistent control. The MR tablets must be swallowed whole with water; they are strictly instructed not to be crushed or chewed as this compromises the modified-release properties. Dose adjustments are typically carried out at intervals of at least one month, allowing the response to be adequately assessed.

Procedural and Population Rules

If a dose is forgotten, the missed dose must be skipped entirely, and the next dose should be taken at the regular scheduled time; a double dose must not be taken to compensate. The same general dosing regimen may be used for older adults (65 years) and patients with mild to moderate renal impairment, though treatment should be initiated conservatively. Use in the pediatric population (under 18 years) is not recommended as safety and efficacy data are not available.

Recent Clinical Evidence

Glimed (Gliclazide): Recent Clinical Evidence

Evidence for use in Type 2 Diabetes Mellitus

Research exploring Gliclazide has primarily centered on its use in adults managing Type 2 Diabetes Mellitus. Studies include numerous Randomized Controlled Trials (RCTs), systematic reviews, and large analyses. The outcomes monitored focused on biomarkers of systemic imbalance, specifically how Gliclazide was evaluated regarding key blood glucose markers (HbA1c, FPG, PPG). Findings describe patterns observed in the studies related to measurements of these blood sugar markers during defined time intervals. Research examined Gliclazide in relation to the observed patterns of blood sugar markers in this population.

Comparison against other treatments

Studies have explored how Gliclazide was evaluated against other antidiabetic agents, including other sulfonylurea compounds and medications like metformin. This comparative evidence was evaluated in trials that monitored key glycemic outcomes. Findings were mixed across some of these studies, and the evidence quality varies, indicating that certainty remains low for drawing definitive conclusions about the outcomes of Gliclazide when studied against certain other treatments.

Long-term Studies and Vascular Follow-up

Research has explored how Gliclazide was evaluated in long-term follow-up regarding microvascular and macrovascular health. Large-scale, long-duration RCTs monitored patients over periods of five years and longer to track the occurrence of events within the measured composite endpoint, such as MACE (Major Adverse Cardiovascular Events). These studies focused on endpoints such as the measured changes in kidney function and the occurrence of MACE. Research highlights changes measured during these extended study periods, reporting patterns observed in the measured changes of these long-term outcomes in the observed populations.

Evidence in Special Populations

Research has explored the use of Gliclazide in specific groups, recognizing that results apply only to the populations studied. Studies have evaluated older adults with Type 2 Diabetes Mellitus, monitoring the balance between achieving blood sugar targets and the potential for low blood sugar. Research also explored Gliclazide in patients who have chronic kidney disease (CKD). For other specific groups, such as those with certain severe comorbidities, data for certain groups remain insufficient, indicating that evidence is limited for understanding long-term outcomes.

What is still uncertain about Glimed (Gliclazide)

Long-term effects, particularly relating to macrovascular outcomes, are not fully established based on studies designed specifically as dedicated Cardiovascular Outcome Trials (CVOTs). In the largest studies exploring these long-term outcomes, Gliclazide was observed as one component within an intensive, multi-drug regimen, making it challenging to separate the outcomes of the Gliclazide agent from the intensive glucose control strategy overall. Furthermore, comparative evidence remains limited for certain head-to-head trials against newer medications.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Glimed (Gliclazide) (FAQ)

Q: How quickly can a person expect Glimed (Gliclazide) to start affecting blood sugar levels?

A: According to official product information, Gliclazide begins to stimulate the release of insulin shortly after administration. The maximum concentration of the drug in the bloodstream is typically reached within 2 to 8 hours after taking a single dose. This initial action is intended to lead to a reduction in blood glucose levels.

Q: Is Glimed considered a 'first line' treatment for Type 2 diabetes?

A: Gliclazide is included on the World Health Organization Model List of Essential Medicines for Type 2 Diabetes treatment. Official documentation indicates it is used when blood sugar control has not been adequately achieved through diet, regular physical exercise, and weight loss alone.

Q: Does Glimed cause weight gain, and if so, how common is it?

A: Regulatory documents list weight increase as a common side effect of Gliclazide. This effect is noted to be common, observed in up to 1 in 10 patients in clinical settings.

Q: Is it normal to feel a bit shaky or sweaty when first starting Glimed?

A: Feeling shaky or sweaty are recognized as common early warning signs of low blood sugar, which is known as hypoglycemia. Because Gliclazide works to lower blood sugar, hypoglycemia is listed as the most common and significant risk associated with its use.

Q: Are there any specific foods or drinks that should be avoided while taking Glimed?

A: The official product information specifically advises against consuming alcohol while taking Gliclazide. This is due to the increased risk of severe low blood sugar (hypoglycemia) that can result from the combination.

Q: Can Glimed affect my ability to drive or operate heavy machinery?

A: Changes in blood glucose levels, such as hypoglycemia, can impair a person's concentration and reaction time. Official warnings indicate that activities requiring concentration, such as driving or operating machinery, may be affected.

Q: Is there a link between Glimed and increased sensitivity to sun exposure?

A: Severe skin reactions are rare but possible with Gliclazide, as noted in official safety information. Although not always explicitly cited, some drugs in the sulfonylurea class have been associated with increased skin sensitivity to sunlight (photosensitivity).

Q: What should be done if I experience a low blood sugar event while sleeping?

A: Official guidance emphasizes that low blood sugar events are managed by immediately consuming fast-acting carbohydrates (sugar). Any severe, prolonged, or recurrent low blood sugar, particularly if it happens during sleep, should lead to urgent medical evaluation.

Q: Can taking Glimed cause a metallic taste in the mouth?

A: While major regulatory documents do not frequently list a metallic taste as a standalone, common side effect of Gliclazide, taste disturbances have been observed in clinical reports, sometimes involving combination therapies with the drug.

Q: Does Glimed have an impact on cholesterol or blood pressure?

A: Regulatory documents indicate that Gliclazide possesses specific properties, separate from its blood sugar lowering action, that have been examined in research regarding effects on blood lipids (fats like cholesterol) and blood clotting factors.

Q: Is Glimed generally safe for long-term use?

A: Gliclazide is indicated for the long-term management of high blood glucose in adults with Type 2 diabetes. Its safety and efficacy profile has been assessed across extended clinical trial periods.

Q: What is the connection between Glimed and a condition called porphyria?

A: Porphyria is not listed as a direct contraindication in the official precautions for Gliclazide. However, special care is advised for patients with a deficiency in Glucose-6-Phosphate Dehydrogenase (G6PD), which is a separate but related type of metabolic condition.

Q: Does Glimed make me feel more hungry than usual?

A: Excessive hunger is a recognized early symptom of low blood sugar (hypoglycemia). Since hypoglycemia is the most common adverse effect of Gliclazide, increased hunger can be an indirect sign that blood sugar is dropping.

Q: Why might a doctor switch me from Metformin to Glimed or add Glimed to my treatment?

A: Official product information indicates Gliclazide is used when a patient's blood glucose levels are not adequately controlled by a primary treatment, such as Metformin, alone. It is therefore used as an option to add to an existing regimen or as an alternative agent when appropriate.

Q: What evidence exists about Glimed's effects on the risk of heart-related problems?

A: Large-scale, long-duration clinical research has been conducted on Gliclazide to track long-term outcomes for patients with Type 2 diabetes. Studies have examined its long-term effects, including patterns observed in microvascular and macrovascular health.

Q: Can Glimed affect my vision?

A: Temporary visual disturbances have been noted in official safety documentation. These changes may occur, particularly when beginning treatment, and are usually related to rapid changes in blood sugar levels.

Q: Is Glimed known to cause low blood cell counts or easy bruising?

A: Official safety documents indicate that rare but serious blood disorders have been reported with Gliclazide. These include aplastic anemia, agranulocytosis, and thrombocytopenia, the last of which can be associated with easy bruising.

Q: Why is it important to tell my doctor about all my medications before starting Glimed?

A: Regulatory documentation lists numerous possible interactions with other drugs, herbal products, and substances. Providing a full list of medications is essential because certain combinations can either increase the risk of low blood sugar or decrease the effectiveness of Gliclazide.

Q: Is the fatigue or tiredness I feel a common side effect of Glimed?

A: Fatigue, weakness, and drowsiness are symptoms that have been observed in connection with low blood sugar (hypoglycemia). Since hypoglycemia is the most common adverse effect of Gliclazide, tiredness can be a related sign.

Q: Are there other medications that can increase the chance of low blood sugar while taking Glimed?

A: Yes, regulatory information on interactions lists several types of medications that can potentiate (increase the effect of) Gliclazide, raising the risk of low blood sugar. Examples include Beta-blockers, ACE inhibitors, and certain antifungals like Fluconazole.

Q: Is there an extended-release (slow-release) version of Glimed available?

A: Yes, Gliclazide is available in a modified-release (MR) formulation, which is also commonly called extended-release. This form is specifically designed to control the rate at which the drug is absorbed into the body over a 24-hour period.

Q: What is the difference between Glimed and Metformin from a patient's perspective?

A: Gliclazide is a sulfonylurea that works by stimulating the pancreas to release insulin, a mechanism different from that of Metformin. This difference affects the safety profile, with Gliclazide being associated with an increased risk of hypoglycemia (low blood sugar) and a common side effect of weight gain.

Q: How does Glimed affect the body's use of natural insulin?

A: The primary mechanism of Gliclazide is to stimulate the beta-cells in the pancreas, causing them to release more insulin. Studies also suggest the drug may have an effect that helps to restore or increase the body's sensitivity to circulating insulin.

Q: What happens if I need to have a surgery or medical procedure?

A: Official warnings state that during stress conditions, such as surgery or trauma, temporary conversion to insulin therapy may be considered.

Q: What if I occasionally skip a meal or fast; does this change the risks of Glimed?

A: Official warnings state that the risk of low blood sugar (hypoglycemia) is increased when there is inadequate caloric intake, including when meals are skipped or irregular. This risk is also increased after strenuous or prolonged physical activity.

Q: What is the purpose of the different strengths (e.g., 40 mg, 80 mg) of Glimed tablets?

A: Gliclazide is available in different strengths and formulations to support dose titration, which is the process of adjusting the dose. The dose is adjusted according to the patient’s individual metabolic response and their measured blood glucose levels.

Q: If I feel better, is that a sign the drug is working or can I stop taking it?

A: Gliclazide is prescribed for the long-term management of a chronic condition, Type 2 diabetes. The product information indicates that discontinuation of the drug is associated with a detected loss of adequate blood glucose-lowering response or the advice of a prescriber.

How should Glimed (Gliclazide) be stored and disposed of?

How to Store and Dispose of Glimed (Gliclazide)

The storage and disposal of Gliclazide must strictly adhere to the conditions documented in official regulatory labeling to maintain product stability and ensure safety.

Official Storage and Handling Requirements

Requirement Category	Official Requirement Stipulations
Temperature Conditions	Store the product in a cool, dry place, typically below 25 C or within 15 C to 30 C.
Packaging	Keep the medicine in its original package to ensure protection and maintain the 3-year shelf life.
Child Safety	Mandatory instruction: Gliclazide must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired tablets must be disposed of according to local regulations for medicinal products. The medicine must not be disposed of via wastewater or general household trash when specialized medicine take-back programs are available in the area.

Glimed (Gliclazide)